Now, Libtayo (cemiplimab) is also in the mix. Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant ...

Regeneron Pharmaceuticals ... in combination with oncology drug Libtayo (cemiplimab). The study is currently enrolling patients with metastatic and locally advanced solid tumors who have exhausted ...

Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Shares of Regeneron Pharmaceuticals ... which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell ...

Although the patient population ... point, as Libtayo continues to report growth and the company’s bispecific antibodies post impressive data. Beyond Libtayo, Regeneron's oncology pipeline ...

Regeneron also purchased rights to the collaboration's PD-1 antibody Libtayo, which could serve ... another chronic disease with a large patient population. The company also has an extremely ...